The Recall Desk

Recalls

All US Product Recalls

Searchable archive of product recalls from the FDA, USDA FSIS, CPSC, NHTSA, and EPA — translated into plain English, severity-scored from objective criteria, and always linked back to the original government notice.

How to read this listing

Every recall on this list has been scored 1–5 against an objective rubric from the agency’s own classification, presence of reported injuries or deaths, distribution scope, and hazard type. The colored severity badge on each card is the score — 5 (Critical) means deaths or serious injuries are reported, 4 (Severe) means significant injury or hospitalization risk, and 3 (High) means a known hazard with no confirmed harm yet. Filter to 3+ (High and above) if you want to skip routine Class-III notices.

The agency chips above control which streams are visible. FDA spans food, drugs, and medical devices. USDA FSIS is meat, poultry, and processed egg products. CPSC is household consumer products. NHTSA is vehicles, tires, and child seats. Nationwide on a card means the recall affects every US state — most do — while a state list means distribution was limited.

Click any recall to see the full summary, affected lot codes and model numbers, the agency’s own classification, and a direct link back to the original government notice for verification.

Filters

Agency

Category

Minimum severity

Clear filters

9276–9300 of 11860

  • SevereFDA (Drugs)·D-861-2015·2015-04-29

    Attix Pharmaceuticals Recalls Prilocaine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Prilocaine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Prilocaine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-748-2015·2015-04-29

    Attix Pharmaceuticals Recalls Lansoprazole Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of lansoprazole active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.

    Product
    Lansoprazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-730-2015·2015-04-29

    Attix Pharmaceuticals Recalls Imatinib Mesylate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Imatinib Mesylate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Imatinib Mesylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-887-2015·2015-04-29

    Attix Pharmaceuticals Recalls Satraplatin Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Satraplatin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Satraplatin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-783-2015·2015-04-29

    Attix Pharmaceuticals Recalls Methazolamide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Methazolamide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Methazolamide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-821-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ofloxacin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Ofloxacin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Ofloxacin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-541-2015·2015-04-29

    Attix Pharmaceuticals Recalls Betamethasone Sodium Phosphate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Betamethasone Sodium Phosphate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Betamethasone Sodium Phosphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-583-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cidofovir Anhydrous Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cidofovir Anhydrous active pharmaceutical ingredient due to a risk of penicillin cross-contamination during repackaging.

    Product
    Cidofovir Anhydrous active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-523-2015·2015-04-29

    Attix Pharmaceuticals Recalls Aprepitant API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Aprepitant active pharmaceutical ingredient distributed between January 2012 and February 2015 due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Aprepitant active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-601-2015·2015-04-29

    Attix Pharmaceuticals Recalls Croscarmellose Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Croscarmellose Sodium pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Croscarmellose Sodium pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-946-2015·2015-04-29

    Attix Pharmaceuticals Recalls Uridine-5'Triphosphate Trisodium Salt Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Uridine-5'Triphosphate Trisodium Salt active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Uridine-5'Triphosphate Trisodium Salt active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-701-2015·2015-04-29

    Attix Pharmaceuticals Recalls Guanabenz Acetate Due to Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Guanabenz Acetate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Guanabenz Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-814-2015·2015-04-29

    Attix Pharmaceuticals Recalls Natamycin API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Natamycin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging. The recall affects lots distributed nationwide to compounding pharmacies and research organizations.

    Product
    Natamycin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-641-2015·2015-04-29

    Attix Pharmaceuticals Recalls Doxycycline HCI Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Doxycycline HCI active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Doxycycline HCI active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-691-2015·2015-04-29

    Attix Pharmaceuticals Recalls Formestane API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Formestane active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Formestane active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-675-2015·2015-04-29

    Attix Pharmaceuticals Recalls Flibanserin API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Flibanserin active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Flibanserin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-544-2015·2015-04-29

    Attix Pharmaceuticals Recalls Bisacodyl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Bisacodyl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Bisacodyl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-895-2015·2015-04-29

    Simvastatin API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Simvastatin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Simvastatin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-659-2015·2015-04-29

    Etamsylate API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Etamsylate active pharmaceutical ingredient due to potential penicillin cross contamination during repackaging.

    Product
    Etamsylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-621-2015·2015-04-29

    Attix Pharmaceuticals Recalls Desonide API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Desonide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Desonide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-868-2015·2015-04-29

    Progesterone Soy Source Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Progesterone Soy Source active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Progesterone Soy Source active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-807-2015·2015-04-29

    Attix Pharmaceuticals Recalls Montelukast Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Montelukast Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Montelukast Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-620-2015·2015-04-29

    Attix Pharmaceuticals Recalls Desmopressin Acetate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Desmopressin Acetate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Desmopressin Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-849-2015·2015-04-29

    Attix Pharmaceuticals Recalls Potassium Acetate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling all lots of Potassium Acetate active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to a risk of penicillin cross-contamination.

    Product
    Potassium Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-509-2015·2015-04-29

    Attix Pharmaceuticals Recalls Amantadine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Amantadine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Amantadine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide